OncoMatch/Clinical Trials/NCT06975293
STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas
Is NCT06975293 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies multiple treatments including STC-15 in combination with toripalimab and STC-15 monotherapy for solid tumor.
Treatment: STC-15 in combination with toripalimab · STC-15 monotherapy — This early phase oncology trial will be conducted at various study centers to investigate the safety, tolerability, and antitumor activity of STC-15 (a METTL3 inhibitor) in combination with toripalimab (anti- programmed cell death 1 \[PD-1\]) in advanced unresectable or metastatic tumors. The Phase 2 Monotherapy part is an open-label, non-randomized, multicenter Simon's 2-stage design that investigates the safety, tolerability, and antitumor activity of STC-15 in participants with selected, relapsed sarcomas subtypes, dedifferentiated (DD) liposarcoma and leiomyosarcoma (uterine and non-uterine).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Sarcoma
Performance status
ECOG 0–1(Restricted strenuous activity)
ECOG performance status 0 or 1
Prior therapy
Must have received: systemic therapy — advanced sarcoma of selected histologic subtype
Participant must have received at least 2, but no more than 4 prior lines of systemic therapy
Lab requirements
Blood counts
Kidney function
Liver function
Cardiac function
Clinically significant cardiovascular disease or condition [excluded]
Have adequate organ function. Clinically significant cardiovascular disease or condition [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Northwell Health Cancer Institute · Lake Success, New York
- NEXT Houston · Houston, Texas
- NEXT Dallas · Irving, Texas
- NEXT Oncology · San Antonio, Texas
- The START Center · San Antonio, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06975293 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received systemic therapy.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages